Table 1.
Ongoing clinical trials for ATT combination therapies in PCa
| Clinical Trial | Primary Anticancer Agent | Secondary Anticancer Agent | Phase | Current Status | Estimated Completion Date |
|---|---|---|---|---|---|
| LACOG-0415 (NCT02867020) | Abiraterone | Apalutamide | II | Recruiting | December 2020 |
| NCT03419234 | Abiraterone | Cabazitaxel | II | Recruiting | April 1, 2025 |
| NCT02703623 | Abiraterone, Apalutamide | Ipilimumab, Cabazitaxel, Carboplatin | II | Active, not recruiting | May 1, 2020 |
| NCT03072238 | Abiraterone | Ipatasertib | III | Active, not recruiting | November 17, 2023 |
| NCT01485861 | Abiraterone | Ipatasertib or Apitolisib | I/II | Recruiting | April 30, 2021 |
| LATITUDE (NCT01715285) | Abiraterone | LHRH agonists or castration | III | Active, not recruiting | December 31, 2022 |
| NCT03732820 | Abiraterone | Olaparib | III | Recruiting | August 17, 2022 |
| NCT01576172 | Abiraterone | Veliparib | II | Active, not recruiting | March 30, 2020 |
| HERO (NCT03085095) | ADT | Relugolix (Reluminia) | III | Active | November 1, 2021 |
| NCT02913196 | Apalutamide | Abiraterone, Docetaxel | I | Recruiting | June 2022 |
| NCT02106507 | Apalutamide | Everolimus | I | Active, not recruiting | April 2021 |
| NCT01251861 | Bicalutamide | MK2206 (AKT Inhibitor) | II | Active, not recruiting | June 19, 2020 |
| ARNEO (NCT03080116) | Degarelix (GnRH antiagonist) | Apalutamide | II | Recruiting | December 30, 2021 |
| IMbassador250 (NCT03016312) | Enzalutamide | Atezolizumab (Anti-PD-L1) | III | Active, not recruiting | Sept 30, 2020 |
| NCT02833883 | Enzalutamide | CC-115 (Dual DNA-dependent protein kinase and mTOR Inhibitor) | I | Active, not recruiting | July 2021 |
| NCT02207504 | Enzalutamide | Crizotinib (TKI) | I | Active, not recruiting | March 2021 |
| NCT02125084 | Enzalutamide | Everolimus (mTOR Inhibitor) | I | Active, not recruiting | January 2021 |
| NCT03834493 | Enzalutamide | Pembrolizumab | III | Recruiting | April 30, 2024 |
| NCT01867333 | Enzalutamide | PROSTVAC | II | Active, not recruiting | January 1, 2021 |
| NCT00450463 | Flutamide | PROSTVAC | II | Completed (No compiled results) | June 8, 2017 |
| NCT03488810 | LHRH, Radiation | Apalutamide | III | Not yet recruiting | June 15, 2026 |
To date, there are many active clinical trials analyzing the efficacy of combination trials in advanced PCa and CRPCa, many based on the preclinical studies mentioned above. Here we have listed some studies of interest that focus on combinations with ATTs will have results shortly.